Mass General Brigham
-
healthMass General Brigham Study Links Daily Walking to Delayed Alzheimer’s Onset
New research from Mass General Brigham indicates walking 5,000 to 7,500 steps daily may delay cognitive decline by seven years in adults with elevated amyloid-beta levels.
-
healthDiabetes Drug Dapagliflozin Slashes Heart Failure Risk in Genetic Carriers
Harvard, MIT, and Mass General Brigham researchers reveal dapagliflozin dramatically reduces heart failure hospitalizations in patients with inherited cardiomyopathy variants, marking a major step in precision preventive cardiology.
-
healthAI Facial Analysis Predicts Cancer Survival Rates
New AI tool, FaceAge, analyzes facial changes over time to offer non-invasive cancer prognosis and refine personalized treatment plans for patients.
-
healthExcessive Daytime Napping in Seniors Linked to Higher Mortality Risk, Study Warns
New research suggests that frequent and prolonged daytime naps in older adults may signal underlying health issues and are associated with increased mortality rates. Experts highlight the potential for nap patterns as an early health detection metric.
-
healthNew Blood Test Shows Promise for Early Alzheimer's Prediction
Groundbreaking research indicates a blood biomarker, pTau217, could identify Alzheimer's risk years before symptoms manifest, potentially revolutionizing early detection and intervention.
-
healthAI Struggles with Critical Patient Diagnosis, Study Reveals
New research shows generative AI fails over 80% of the time in primary patient diagnosis, highlighting the need for human oversight in healthcare.
-
healthALS Breakthrough Trial Launches for Pridopidine Drug
Phase 3 PREVAiLS study begins enrollment as pridopidine shows promise for slowing ALS progression in early-stage patients.
-
healthVitamin D May Reduce Risk of Long COVID, Study Finds
A Mass General Brigham study suggests high-dose vitamin D supplementation could lower the risk of developing long COVID symptoms.